je.st
news
Home
› Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA (pembrolizumab) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA (pembrolizumab) Combination Trial
2015-12-10 12:30:08| Merck.com - Product News
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lillys cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Mercks KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. Language: English read more
Tags: trial
combination
expand
adding
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||